card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Published 4 years ago • 1.5K plays • Length 4:34Download video MP4
Download video MP3
Similar videos
-
4:06
combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
5:59
lupsma vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...
-
5:56
card trial in metastatic crpc
-
6:23
dr t p sahoo | cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
1:22
cabazitaxel improves rpfs in patients with mcrpc
-
1:37
cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
-
0:42
tom beer, md, on impressions of the card study investigating cabazitaxel in mcrpc patients
-
5:46
metastatic castration-resistant prostate cancer – new learnings and perspectives
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
8:12
the use of abiraterone and enzalutamide against crpc
-
2:07
chaarted2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic crpc
-
0:58
andrew armstrong, md, on impressions of the card study investigating cabazitaxel in mcrpc patients
-
2:03
key takeaways from keynote-365 in metastatic castration-resistant prostate cancer
-
19:51
metastatic prostate cancer - interpreting negative trial results